Boehringer Increasingly Looking Outside For Oncology Growth

The private company has stressed home-grown candidates, but it's making more external plays as it builds oncology as one of the pillars of the business.

Boehringer Ingelheim GMBH is becoming more active in the competitive oncology business development marketplace as the firm tries to broaden its footprint in cancer.

The closely guarded private firm has made oncology one of its core pillars as it has sharpened its research and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category